The Incidence and Cost of Hospitalization for 5-FU Toxicity among Medicare Beneficiaries with Metastatic Colorectal Cancer
- 1 January 2002
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 5 (1), 35-43
- https://doi.org/10.1046/j.1524-4733.2002.51083.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Use of medicare claims data to measure county-level variations in the incidence of colorectal carcinomaCancer, 1998
- A Prospective Randomized Study Comparing High- and Low-Dose Leucovorin Combined With Same-Dose 5-Fluorouracil in Advanced Colorectal CancerAmerican Journal of Clinical Oncology, 1998
- Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.Journal of Clinical Oncology, 1998
- Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.Journal of Clinical Oncology, 1997
- A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancerAnnals of Oncology, 1997
- Estimating Medical Costs from Incomplete Follow-Up DataBiometrics, 1997
- Ability of Medicare Claims Data and Cancer Registries to Identify Cancer Cases and TreatmentAmerican Journal of Epidemiology, 1997
- Colorectal cancer???an undertreated diseaseAnti-Cancer Drugs, 1996
- Surgery for colorectal cancer: Race-related differences in rates and survival among Medicare beneficiaries.American Journal of Public Health, 1996
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958